ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Regeneron Pharmaceuticals and Avalanche Biotechnologies are partnering to discover, develop, and commercialize gene therapy products for the treatment of eye diseases. Work will center on gene therapy vectors and proprietary molecules discovered jointly by Avalanche and Regeneron and developed using Avalanche’s adeno-associated virus-based gene-sequencing technology. Avalanche will receive up to $640 million when it achieves certain development and regulatory milestones. It will also receive royalties on sales of products resulting from the collaboration. Regeneron will get unspecified first rights to Avalanche’s gene therapy product AVA-101, which is under development to treat wet age-related macular degeneration.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X